Free Trial
NASDAQ:DMAC

DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis

DiaMedica Therapeutics logo
$5.38 -1.03 (-16.07%)
(As of 05:26 PM ET)

About DiaMedica Therapeutics Stock (NASDAQ:DMAC)

Key Stats

Today's Range
$5.16
$6.04
50-Day Range
$4.01
$6.41
52-Week Range
$2.14
$6.41
Volume
202,865 shs
Average Volume
60,435 shs
Market Capitalization
$230.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DiaMedica Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
35th Percentile Overall Score

DMAC MarketRank™: 

DiaMedica Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 745th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    DiaMedica Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    DiaMedica Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about DiaMedica Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for DiaMedica Therapeutics are expected to decrease in the coming year, from ($0.59) to ($0.80) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of DiaMedica Therapeutics is -9.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of DiaMedica Therapeutics is -9.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    DiaMedica Therapeutics has a P/B Ratio of 3.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.35% of the outstanding shares of DiaMedica Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    DiaMedica Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in DiaMedica Therapeutics has recently decreased by 12.17%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    DiaMedica Therapeutics does not currently pay a dividend.

  • Dividend Growth

    DiaMedica Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.35% of the outstanding shares of DiaMedica Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    DiaMedica Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in DiaMedica Therapeutics has recently decreased by 12.17%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for DiaMedica Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for DMAC on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 2 people have added DiaMedica Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, DiaMedica Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.20% of the stock of DiaMedica Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 10.12% of the stock of DiaMedica Therapeutics is held by institutions.

  • Read more about DiaMedica Therapeutics' insider trading history.
Receive DMAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DMAC Stock News Headlines

We recommended Palantir in 2021, now we’re recommending this...
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
DiaMedica Therapeutics doses first patient in Phase 2 DM199 trial
See More Headlines

DMAC Stock Analysis - Frequently Asked Questions

DiaMedica Therapeutics' stock was trading at $2.84 at the start of the year. Since then, DMAC stock has increased by 89.4% and is now trading at $5.38.
View the best growth stocks for 2024 here
.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announced its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03.

DiaMedica Therapeutics (DMAC) raised $18 million in an IPO on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

DiaMedica Therapeutics' top institutional investors include Geode Capital Management LLC (0.72%), Blue Trust Inc. (0.10%) and Point72 Asia Singapore Pte. Ltd. (0.02%). Insiders that own company stock include Koch Thomas Von, David J Wambeke, Randall Michael Giuffre, Dietrich John Pauls and Scott Kellen.
View institutional ownership trends
.

Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that DiaMedica Therapeutics investors own include NVIDIA (NVDA), ADMA Biologics (ADMA), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX), Ardelyx (ARDX) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
8/07/2024
Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DMAC
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$8.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+30.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-19,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.35 per share

Miscellaneous

Free Float
39,682,000
Market Cap
$230.05 million
Optionable
Optionable
Beta
1.51
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:DMAC) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners